CymaBay Therapeutics, Inc.

NasdaqGS:CBAY Stok Raporu

Piyasa değeri: US$3.7b

CymaBay Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

CymaBay Therapeutics CEO'su Sujal Shah, Mar2017 tarihinde atandı, in görev süresi 6.75 yıldır. in toplam yıllık tazminatı $ 2.56M olup, şirket hissesi ve opsiyonları dahil olmak üzere 23% maaş ve 77% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.35% ine doğrudan sahiptir ve bu hisseler $ 13.20M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 7 yıldır.

Anahtar bilgiler

Sujal Shah

İcra Kurulu Başkanı

US$2.6m

Toplam tazminat

CEO maaş yüzdesi23.0%
CEO görev süresi7yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresi3.5yrs
Yönetim Kurulu ortalama görev süresi7yrs

Son yönetim güncellemeleri

Recent updates

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Dec 22
Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

Dec 28
CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01

Aug 11

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

Jul 13
Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

CymaBay: Long-Term Potential Based On Prior PBC Trial Results

Jun 27

Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?

Mar 17
Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?

Why I've Taken A 'Starter' Position In CymaBay Therapeutics

Jan 20

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

Dec 03
Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth

May 15
We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth

We're Hopeful That CymaBay Therapeutics (NASDAQ:CBAY) Will Use Its Cash Wisely

Jan 29
We're Hopeful That CymaBay Therapeutics (NASDAQ:CBAY) Will Use Its Cash Wisely

CymaBay Therapeutics (CBAY) Presents At AASLD 2020 Conference- Slideshow

Nov 17

CymaBay Is Clawing Back, Now We Just Need Pipeline Conversion

Nov 08

CymaBay Therapeutics EPS in-line

Nov 05

CEO Tazminat Analizi

Sujal Shah'un ücretlendirmesi CymaBay Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Dec 31 2023n/an/a

-US$105m

Sep 30 2023n/an/a

-US$90m

Jun 30 2023n/an/a

-US$81m

Mar 31 2023n/an/a

-US$107m

Dec 31 2022US$3mUS$590k

-US$106m

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$104m

Mar 31 2022n/an/a

-US$100m

Dec 31 2021US$2mUS$550k

-US$90m

Sep 30 2021n/an/a

-US$79m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$55m

Dec 31 2020US$3mUS$510k

-US$51m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$80m

Mar 31 2020n/an/a

-US$93m

Dec 31 2019US$3mUS$510k

-US$103m

Sep 30 2019n/an/a

-US$93m

Jun 30 2019n/an/a

-US$85m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$2mUS$452k

-US$73m

Sep 30 2018n/an/a

-US$58m

Jun 30 2018n/an/a

-US$48m

Mar 31 2018n/an/a

-US$39m

Dec 31 2017US$5mUS$393k

-US$28m

Tazminat ve Piyasa: Sujal 'nin toplam tazminatı ($USD 2.56M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 6.60M ).

Tazminat ve Kazançlar: Sujal şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Sujal Shah (50 yo)

7yrs

Görev süresi

US$2,561,783

Tazminat

Mr. Sujal A. Shah serves as Director at Tvardi Therapeutics, Inc. since January 2021. He has been the Chief Executive Officer and President of Cymabay Therapeutics, Inc, since November 6, 2017. Mr. Shah se...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Sujal Shah
President7yrsUS$2.56m0.35%
$ 13.2m
Charles McWherter
President of Research & Development and Chief Scientific Officer11.2yrsUS$1.23m0.041%
$ 1.5m
Paul Quinlan
General Counsel3.4yrsUS$1.10m0.061%
$ 2.3m
Harish Shantharam
CFO, Principal Accounting & Financial Officerless than a yearVeri yok0.018%
$ 653.5k
Ken Boehm
Senior Vice President of Human Resources3.7yrsVeri yokVeri yok
Patrick O'Mara
Senior Vice President of Business Development7.2yrsVeri yokVeri yok
Robert Martin
Senior Vice President of Manufacturing & Nonclinical Development8.9yrsVeri yokVeri yok
Klara Dickinson-Eason
Chief Regulatory & Quality Assurance Officer3.4yrsUS$1.24m0.018%
$ 681.8k
Becki Filice
Senior Vice President of Portfolio & Product Leadership3.3yrsVeri yokVeri yok
Ben Kozub
Head of Commercialless than a yearVeri yokVeri yok

3.5yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim: CBAY 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Sujal Shah
President6.8yrsUS$2.56m0.35%
$ 13.2m
Thomas Wiggans
Independent Director2.9yrsUS$207.94k0%
$ 0
Jerrold Olefsky
Member of Clinical Advisory Board and Member of Scientific Advisory Boardno dataVeri yokVeri yok
Caroline Loewy
Independent Director7.3yrsUS$215.44k0%
$ 0
Mayer Davidson
Member of Clinical Advisory Boardno dataVeri yokVeri yok
Robert Sherwin
Member of Clinical Advisory Boardno dataVeri yokVeri yok
Gerald Shulman
Member of Clinical Advisory Boardno dataVeri yokVeri yok
Morris Birnbaum
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Steven Shoelson
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Robert Gelfand
Member of Clinical Advisory Boardno dataVeri yokVeri yok
David Orloff
Member of Clinical Advisory Boardno dataVeri yokVeri yok
Robert Wills
Independent Chairman9yrsUS$245.44k0.026%
$ 974.1k

7.0yrs

Ortalama Görev Süresi

69yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CBAY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7 yıldır).